The Ambulatory Medical Assistance (AMA) programme during active‐phase treatment in patients with haematological malignancies: A cost‐effectiveness analysis

Anne‐sophie Michallet (), Stephanie Malartre, Elodie Vignaud, Alexiane Bocquet, Pascale Sontag, Christelle Galvez, Jean‐yves Blay (), Pierre Heudel, Alexandre Vimont (), Martin Blachier, Marie Ferrua, Olivier Mir and Etienne Minvielle ()
Additional contact information
Etienne Minvielle: CRG I3 - Centre de recherche en gestion i3 - X - École polytechnique - IP Paris - Institut Polytechnique de Paris - Université Paris-Saclay - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: Context: The need for patient navigator is growing, and there is a lack of cost evaluation, especially during survivorship. Objective: The objective of this study is to evaluate the cost-effectiveness of an Ambulatory Medical Assistance (AMA) programme in patients with haematological malignancies (HM). Design: A cost-effectiveness analysis of the AMA programme was performed compared to a simulated control arm. Setting: An interventional, single-arm and prospective study was conducted in a French reference haematology–oncology centre between 2016 and 2020. Participants: Adult patients were enrolled with histologically documented malignant haematology, during their active therapy phase, and treated either by intravenous chemotherapy or oral therapy. Methods: An extrapolation of the effectiveness was derived from a similar nurse monitoring programme (CAPRI study). Cost effectiveness of the programme was evaluated through adverse events of Grade 3 or 4 avoided in different populations. Results: Included patient (n=797) from the AMA programme were followed during125 days (IQR: 0–181), and adverse events (Grade 3/4) were observed in 10.1% of patients versus 13.4% in the simulated control arm. The overall cost of AE avoided was estimated to€81,113, leading to an ICER of€864. Conclusion: The AMA programme was shown to be cost-effective compared to a simulated control arm with no intervention

Keywords: adverse events; chemotherapy; cost-effectiveness; healthcare quality; monitoring; oncologicnursing (search for similar items in EconPapers)
Date: 2022-11
References: Add references at CitEc
Citations:

Published in European Journal of Cancer Care, 2022, 31 (6), ⟨10.1111/ecc.13709⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-03889400

DOI: 10.1111/ecc.13709

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().